{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B+complex&page=18", "query": { "intervention": "B complex", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 912, "total_pages": 92, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B+complex&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B+complex&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T13:05:42.692Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00529503", "title": "A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "SGN-40", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 151, "start_date": "2007-09", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2015-02-25", "last_synced_at": "2026-10-19T13:05:42.692Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00529503" }, { "nct_id": "NCT06404086", "title": "RECOVER-SLEEP: Platform Protocol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID", "Long COVID-19", "Hypersomnia", "Sleep Disturbance" ], "interventions": [ { "name": "Modafinil", "type": "DRUG" }, { "name": "Modafinil Placebo", "type": "DRUG" }, { "name": "Solriamfetol", "type": "DRUG" }, { "name": "Solriamfetol Placebo", "type": "DRUG" }, { "name": "Melatonin", "type": "DRUG" }, { "name": "Melantonin Placebo", "type": "DRUG" }, { "name": "Tailored lighting (TL) Active", "type": "DEVICE" }, { "name": "Tailored lighting (TL) Placebo", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 830, "start_date": "2024-07-31", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-19T13:05:42.692Z", "location_count": 47, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06404086" }, { "nct_id": "NCT04671667", "title": "Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Proton Beam Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 188, "start_date": "2021-04-27", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-19T13:05:42.692Z", "location_count": 178, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 128 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04671667" }, { "nct_id": "NCT04318548", "title": "Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infections, Meningococcal" ], "interventions": [ { "name": "Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)", "type": "COMBINATION_PRODUCT" }, { "name": "Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT", "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "16 Years to 18 Years" }, "enrollment_count": 945, "start_date": "2020-08-25", "completion_date": "2023-11-21", "has_results": true, "last_update_posted_date": "2025-03-04", "last_synced_at": "2026-10-19T13:05:42.692Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Bell Gardens, California • Los Angeles, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bell Gardens", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Roseville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04318548" }, { "nct_id": "NCT06915428", "title": "Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Preterm Birth Complication", "Preterm Birth", "Preterm Birth Recurrence", "Preeclampsia", "Preeclampsia (PE)", "Hypertensive Disorders of Pregnancy", "Support Program", "Stress", "Resilience, Psychological", "Empowerment, Patient", "Emotional Stress", "Pregnancy", "Pregnancy Complications", "Pregnancy Induced Hypertension", "Neonates and Preterm Infants", "Cervical Insufficiency", "Social Determinants of Health (SDOH)", "Cervical Shortening", "Disparities in Pregnancy Complications", "Disparities", "Prenatal Care", "Care Coordination" ], "interventions": [ { "name": "Care coordination", "type": "BEHAVIORAL" }, { "name": "Electronic massage", "type": "BEHAVIORAL" }, { "name": "support gift #1", "type": "BEHAVIORAL" }, { "name": "Support gift #2", "type": "BEHAVIORAL" }, { "name": "Support gift #3", "type": "BEHAVIORAL" }, { "name": "Support gift #4", "type": "BEHAVIORAL" }, { "name": "Additional PTBCARE+ support", "type": "BEHAVIORAL" }, { "name": "Stress reduction toolkit - Visit 1 (V1)", "type": "BEHAVIORAL" }, { "name": "PTBCARE+ mobile application (app) and website", "type": "BEHAVIORAL" }, { "name": "Sleep, meditation, and Wellness app", "type": "BEHAVIORAL" }, { "name": "Emergency low blood sugar kit", "type": "BEHAVIORAL" }, { "name": "Low dose aspirin (LDA)", "type": "BEHAVIORAL" }, { "name": "Visit #2 Stress Reduction Toolkit", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1228, "start_date": "2026-10-01", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-19T13:05:42.692Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06915428" }, { "nct_id": "NCT02098343", "title": "p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53" ], "interventions": [ { "name": "APR-246", "type": "DRUG" }, { "name": "Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aprea Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 247, "start_date": "2014-03", "completion_date": "2019-04", "has_results": true, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-10-19T13:05:42.692Z", "location_count": 15, "location_summary": "Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02098343" }, { "nct_id": "NCT02419495", "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Fallopian Tube Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Ovarian Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Primary Peritoneal Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Melanoma", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2015-06-26", "completion_date": "2024-09-16", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-19T13:05:42.692Z", "location_count": 5, "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more", "locations": [ { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "League City", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419495" }, { "nct_id": "NCT00598169", "title": "Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 23, "start_date": "2007-11", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2020-08-10", "last_synced_at": "2026-10-19T13:05:42.692Z", "location_count": 17, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00598169" }, { "nct_id": "NCT00324831", "title": "GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "autologous immunoglobulin idiotype-KLH conjugate vaccine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "sargramostim", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "Intervention/procedure", "type": "PROCEDURE" }, { "name": "antibody therapy", "type": "PROCEDURE" }, { "name": "biological therapy", "type": "PROCEDURE" }, { "name": "chemotherapy", "type": "PROCEDURE" }, { "name": "colony-stimulating factor therapy", "type": "PROCEDURE" }, { "name": "cytokine therapy", "type": "PROCEDURE" }, { "name": "monoclonal antibody therapy", "type": "PROCEDURE" }, { "name": "non-specific immune-modulator therapy", "type": "PROCEDURE" }, { "name": "therapeutic procedure", "type": "PROCEDURE" }, { "name": "tumor cell derivative vaccine", "type": "PROCEDURE" }, { "name": "vaccine therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Favrille", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 480, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-10-19T13:05:42.692Z", "location_count": 2, "location_summary": "Beverly Hills, California • Chapel Hill, North Carolina", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324831" }, { "nct_id": "NCT00861705", "title": "Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Male Breast Carcinoma", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage IIIA Breast Cancer AJCC v7", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 454, "start_date": "2009-07-21", "completion_date": "2025-09-02", "has_results": true, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-19T13:05:42.692Z", "location_count": 448, "location_summary": "Jonesboro, Arkansas • Rogers, Arkansas • Berkeley, California + 309 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861705" } ] }